COSM Cosmos Health Inc.
Wholesale-Drugs, Proprietaries & Druggists' Sundries · Nasdaq · SEC CIK 1474167 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY33.8%
TTM net income YoY-13.1%
TTM EPS YoY35.6%
Revenue 3-yr CAGR14.8%
Net income 3-yr CAGR—
Margins
Gross margin10.3%
Operating margin-24.9%
Net margin-33.1%
FCF margin-13.5%
EBITDA margin-23.0%
Returns
ROE-104.0%
ROA-39.6%
ROIC (approx.)-54.8%
Asset turnover1.20x
Leverage & solvency
Liabilities / assets66.4%
Debt / equity0.15x
Current ratio1.05x
Interest coverage-7.80x
Cash quality & payout
Operating cash flow / net income0.40x
Accruals ratio-23.6%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $65.27M | $54.43M | $53.38M | $50.35M | $56.24M |
| Cost of revenue | $57.38M | $50.12M | $49.03M | $44.39M | $47.91M |
| Gross profit | $7.90M | $4.31M | $4.35M | $5.96M | $8.33M |
| R&D expense | $519,363 | $533,293 | $164,859 | — | — |
| SG&A expense | $15.62M | $11.73M | $19.64M | $10.18M | $9.21M |
| Operating income | -$16.70M | -$15.54M | -$21.83M | -$7.47M | -$4.53M |
| Interest expense | $1.90M | $1.01M | $866,476 | $2.35M | $2.82M |
| Pretax income | -$19.14M | -$16.18M | -$18.54M | -$13.06M | -$7.85M |
| Income tax | $0 | $0 | $0 | -$775,051 | $114,010 |
| Net income | -$19.14M | -$16.18M | -$18.54M | -$13.83M | -$7.96M |
| EBITDA | -$15.34M | -$14.33M | -$21.22M | -$7.29M | -$4.18M |
| EPS (basic) | -0.63 | -1.17 | -2.15 | -33.16 | -23.74 |
| EPS (diluted) | -0.63 | -1.17 | -2.15 | -33.16 | -23.74 |
| Weighted avg. shares (diluted) | 30.29M | 19.15M | — | 1.93M | 656,933 |
| Banking | |||||
| Noninterest expense | — | — | — | $216,182 | — |
| Balance sheet | |||||
| Cash & equivalents | $715,674 | $315,105 | $3.83M | $20.75M | $286,487 |
| Short-term investments | $46,158 | $21,148 | $20,075 | $14,881 | $11,468 |
| Receivables | $19.63M | $13.48M | $19.76M | $23.69M | — |
| Inventory | $5.78M | $4.36M | $4.79M | $3.45M | $3.15M |
| Current assets | $38.39M | $25.46M | $36.61M | $56.37M | $39.83M |
| PP&E, net | $10.58M | $9.69M | $10.33M | $1.82M | $1.89M |
| Goodwill | $49,697 | $49,697 | $49,697 | $49,697 | $49,698 |
| Intangibles | $7.52M | $7.71M | $7.76M | $657,217 | $436,069 |
| Total assets | $65.48M | $54.31M | $66.01M | $68.04M | $49.43M |
| Current liabilities | $38.27M | $25.76M | $24.32M | $21.75M | $29.93M |
| Short-term debt | — | — | $1.91M | — | — |
| Long-term debt | $3.78M | $4.11M | $1.33M | $5.02M | $477,637 |
| Total debt | $3.78M | $4.11M | $3.24M | $5.02M | $477,637 |
| Total liabilities | $47.05M | $29.78M | $29.97M | $28.38M | $45.05M |
| Shareholders' equity | $18.42M | $24.53M | $36.04M | $39.28M | $4.38M |
| Net debt | $3.06M | $3.79M | -$597,560 | -$15.73M | $191,150 |
| Shares outstanding | 41.07M | 23.60M | 15.90M | 10.59M | 686,283 |
| Cash flow statement | |||||
| Operating cash flow | -$8.45M | -$7.72M | -$15.64M | -$14.87M | -$7.10M |
| Capital expenditure | $55,675 | $418,075 | $1.31M | $74,207 | $581,398 |
| Free cash flow | -$8.50M | -$8.14M | -$16.95M | -$14.94M | -$7.68M |
| Investing cash flow | -$2.01M | -$798,269 | -$13.76M | -$21,497 | -$826,817 |
| Financing cash flow | $14.06M | $5.05M | $12.69M | $35.05M | $7.27M |
| Depreciation & amortization | $1.36M | $1.22M | $614,377 | $188,890 | $352,422 |
| Stock-based compensation | $2.31M | $1.69M | $577,931 | $24,401 | $5.90M |
| Share buybacks | — | $0 | $100,452 | — | $376,863 |
Free plan shows the latest 5 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-19 06:28.